Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Curcuminoids Modify Lipid Profile in Type 2 Diabetes Mellitus: A Randomized Controlled Trial Publisher Pubmed



Panahi Y1 ; Khalili N2 ; Sahebi E3 ; Namazi S3 ; Reiner Z4 ; Majeed M5 ; Sahbekar A6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
  2. 2. Department of Endocrinology, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Pharmacotherapy, School of Pharmacy, Shiraz University of Medical Sciences, P.O. Box 1583, Shiraz, Iran
  4. 4. University Hospital Center Zagreb, Department of Internal medicine, University of Zagreb School of Medicine, Kispaticeva 12, Zagreb, Croatia
  5. 5. Sabinsa Corporation, East Windsor, NJ, United States
  6. 6. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Complementary Therapies in Medicine Published:2017


Abstract

Background Type 2 diabetes (T2D) is an established risk factor for cardiovascular disease (CVD) and is associated with disturbed metabolism of lipids and lipoproteins. Curcuminoids are natural products with anti-diabetic and lipid-modifying actions but their efficacy in improving dyslipidemia in diabetic individuals has not been sufficiently studied. Objective To investigate the efficacy of supplementation with curcuminoids, plus piperine as an absorption enhancer, in improving serum lipids in patients with T2D. Methods In this 12-week randomized double-blind placebo-controlled trial, subjects with T2D (n = 118) were assigned to curcuminoids (1000 mg/day plus piperine 10 mg/day) or placebo plus standard of care for T2D. Serum concentrations of lipids including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), lipoprotein(a) [Lp(a)], and non-HDL-C were determined at baseline and at the end of trial. Results Between-group comparison of change in the study parameters revealed significant reductions in serum levels of TC (−21.86 ± 25.78 versus −17.06 ± 41.51, respectively; p = 0.023), non-HDL-C (−23.42 ± 25.13 versus −16.84 ± 41.42, respectively; p = 0.014) and Lp(a) (−1.50 ± 1.61 versus −0.34 ± 1.73, respectively; p = 0.001) and elevations in serum HDL-C levels (1.56 ± 4.25 versus −0.22 ± 4.62, respectively; p = 0.048) in the curcuminoids group as compared with the placebo group (p < 0.05). Serum TG and LDL-C changes did not show any significant difference between the study groups (p > 0.05). Conclusion Curcuminoids supplementation can reduce serum levels of atherogenic lipid indices including non-HDL-C and Lp(a). Therefore, curcuminoids supplementation could contribute to a reduced risk of cardiovascular events in dyslipidemic patients with T2D. © 2017 Elsevier Ltd
Other Related Docs
19. Dietary Polyphenols for Atherosclerosis: A Comprehensive Review and Future Perspectives, Critical Reviews in Food Science and Nutrition (2019)
28. Turmeric, Pepper, Cinnamon, and Saffron Consumption and Mortality, Journal of the American Heart Association (2019)
46. Targeting Mirna by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver, Evidence-based Complementary and Alternative Medicine (2021)